Company Filing History:
3 out of 27 
1 out of 119 
Years Active: 2013-2018
Title: **Damian McCartan: Innovator in Cancer Research**
Introduction
Damian McCartan, an accomplished inventor based in Dublin, Ireland, has made significant contributions to the field of cancer research. With a portfolio of three patents, Damian's work primarily focuses on developing diagnostic methods and therapeutic agents for metastatic breast cancer. His innovative approaches have drawn attention from various research institutions and healthcare organizations.
Latest Patents
Among Damian's most noteworthy inventions is his latest patent concerning ADAM22. This patent outlines a method of diagnosing the metastatic potential of breast cancer in patients. The process involves assessing a breast cancer tumor sample for the expression of A Disintegrin and Metalloproteinase 22 (ADAM22). Notably, increased expression of ADAM22 indicates a heightened risk of metastasis compared to patients who are ADAM22 negative. Additionally, the patent describes a novel therapeutic agent, which may include leucine-rich glioma-inactivated protein 1 (LGI1) or an LGI1 peptide mimic. This agent has the potential to inhibit the migration of endocrine-resistant breast cancer cells, offering new avenues for treatment.
Career Highlights
Damian's career has been marked by his association with esteemed institutions such as the Royal College of Surgeons in Ireland and University College Dublin. His experience in these prominent organizations has equipped him with the skills and knowledge necessary to advance his research in oncology and innovation.
Collaborations
Throughout his career, Damian has collaborated with notable figures in the field, including Leonie Young and Christopher Byrne. These partnerships have allowed him to further enhance his research and develop impactful solutions for cancer treatment.
Conclusion
Damian McCartan continues to pave the way for innovation in cancer diagnostics and therapy. His patented methods and agents hold promise for improving outcomes for breast cancer patients. With a solid background in research and collaboration, Damian’s contributions to the field will likely leave a lasting impact on cancer care and treatment.